Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
With
Heffter Research Institute
In this placebo-controlled, blinded study, individuals with depression will participate in 2 experimental sessions approximately 4 weeks apart during which they will receive two of the following three interventions: 1) placebo, 2) low dose psilocybin (0.1 mg/kg), and 3) medium dose psilocybin (0.3 mg/kg).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with Major Depressive Disorder (MDD), single or recurrent episode, and currently experiencing a Major Depressive Episode (MDE)
Failed to achieve a satisfactory clinical response to at least one adequate antidepressant trial during the current depressive episode
Currently engaged in treatment with a mental health clinician
You may not be if
Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)
Axis I psychotic disorder in first degree relative
Currently taking a conventional antidepressant medication
Unstable medical or neurological conditions
Significant cognitive disorders
History of intolerance to drugs known to significantly alter perception e.g., psilocybin, LSD, salvinorin A, mescaline, etc.
Pregnant, breastfeeding, lack of adequate birth control
Urine toxicology positive to drugs of abuse on experimental test days
Clareo Health | Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
